Search research articles
Contact Us
Filters
Showing results (11-20 of 17) with videos related to
Page
of 2
Sort By:
You have reached the last page of results.
This site can display upto 17 results.
Human Pathology
|
April 21, 2012
Combined metallothioneins and p53 proteins expression as a prognostic marker in patients with Dukes stage B and C colorectal cancer
J M Arriaga, I A Bravo, L Bruno, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
March 30, 2019
T-cell bispecific antibodies in node-positive breast cancer: novel therapeutic avenue for MHC class I loss variants
M Messaoudene, T P Mourikis, J Michels, et al.
Cell Research
|
September 5, 2019
Sustained Type I interferon signaling as a mechanism of resistance to PD-1 blockade
Nicolas Jacquelot, Takahiro Yamazaki, Maria P Roberti, et al.
Science (New York, N.Y.)
|
November 7, 2015
Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota
Marie Vétizou, Jonathan M Pitt, Romain Daillère, et al.
Science (New York, N.Y.)
|
November 4, 2017
Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors
Bertrand Routy, Emmanuelle Le Chatelier, Lisa Derosa, et al.
Nature Communications
|
September 21, 2017
Predictors of responses to immune checkpoint blockade in advanced melanoma
N Jacquelot, M P Roberti, D P Enot, et al.
Nature Medicine
|
July 9, 2021
Gut microbiota signatures are associated with toxicity to combined CTLA-4 and PD-1 blockade
Miles C Andrews, Connie P M Duong, Vancheswaran Gopalakrishnan, et al.
Page
of 2
Search research articles
Search
Showing results (11-20 of 17) with videos related to
Sort By:
Page
of 2
You have reached the last page of results.
This site can display upto 17 results.
Human Pathology
|
April 21, 2012
Combined metallothioneins and p53 proteins expression as a prognostic marker in patients with Dukes stage B and C colorectal cancer
J M Arriaga, I A Bravo, L Bruno, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
March 30, 2019
T-cell bispecific antibodies in node-positive breast cancer: novel therapeutic avenue for MHC class I loss variants
M Messaoudene, T P Mourikis, J Michels, et al.
Cell Research
|
September 5, 2019
Sustained Type I interferon signaling as a mechanism of resistance to PD-1 blockade
Nicolas Jacquelot, Takahiro Yamazaki, Maria P Roberti, et al.
Science (New York, N.Y.)
|
November 7, 2015
Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota
Marie Vétizou, Jonathan M Pitt, Romain Daillère, et al.
Science (New York, N.Y.)
|
November 4, 2017
Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors
Bertrand Routy, Emmanuelle Le Chatelier, Lisa Derosa, et al.
Nature Communications
|
September 21, 2017
Predictors of responses to immune checkpoint blockade in advanced melanoma
N Jacquelot, M P Roberti, D P Enot, et al.
Nature Medicine
|
July 9, 2021
Gut microbiota signatures are associated with toxicity to combined CTLA-4 and PD-1 blockade
Miles C Andrews, Connie P M Duong, Vancheswaran Gopalakrishnan, et al.
Page
of 2